Case Study: Hypertension In Pregnancy - Kita Brown, 3 452285

Case Studyhypertension In Pregnancykita Brown Is A 36 Year Old Black

Case Studyhypertension In Pregnancykita Brown Is A 36 Year Old Black

Analyze the presented case of Kita Brown, a 36-year-old pregnant woman at 30 weeks gestation who reports elevated blood pressure and childbirth-related concerns, to identify differential diagnoses, appropriate treatments, necessary further investigations, assessment priorities, and diagnostic tools suitable for her condition.

Paper For Above instruction

The case of Kita Brown illustrates a critical scenario in obstetric care where hypertensive disorders during pregnancy pose significant risks to both mother and fetus. As a 36-year-old woman at 30 weeks gestation presenting with elevated blood pressure and a history suggestive of hypertensive tendencies, a systematic approach is essential to ensure timely diagnosis and management.

Differential Diagnoses

Initially, the primary differential diagnosis should focus on hypertensive disorders related to pregnancy. The foremost consideration is gestational hypertension, characterized by elevated blood pressure occurring after 20 weeks of pregnancy without proteinuria or other systemic features. Given her BP readings of 162/90 and 166/88 mm Hg upon presentation, this diagnosis is plausible.

Pre-eclampsia is another critical differential, especially considering her history of pregnancy-induced hypertension and prior pre-eclampsia, although her current labs—including protein to creatine ratio—are normal. Still, pre-eclampsia can present subtly and can escalate rapidly, warranting close monitoring.

A third differential is chronic hypertension, which would be relevant given her history of hypertension prior to pregnancy and use of HCTZ. However, her blood pressure has been noted as "pretty normal" before pregnancy, which may argue against this unless she has undiagnosed longstanding hypertension.

Additionally, considering other causes of elevated blood pressure such as secondary hypertension from renal or endocrine causes (e.g., renal artery stenosis, primary aldosteronism) is important but less likely given her history and presentation.

Treatment Strategies

The management of pregnancy-induced hypertensive disorders involves antihypertensive therapy to control blood pressure and prevent progression to severe pre-eclampsia or eclampsia. First-line medications safe for use in pregnancy include labetalol, nifedipine, and methyldopa. Since she was prescribed labetalol previously but did not take it regularly, re-initiation with close monitoring is advisable.

Additionally, hospitalization or increased surveillance may be necessary depending on her blood pressure levels and any emergence of symptoms or signs of disease progression. Given her BP readings and gestational age, interventions to lower BP to safe levels (

Further, patient education regarding warning signs such as vision changes, severe headaches, epigastric pain, or decreased fetal movement is vital, as is planning for more frequent prenatal assessments.

Further Information Needed

To optimize care, additional data are necessary, including detailed urine analysis for proteinuria, additional blood tests such as liver enzymes, platelet counts, renal function tests, and assessment of fetal well-being via ultrasound or non-stress tests (NST). Monitoring for signs of pre-eclampsia and eclampsia or HELLP syndrome is critical.

Information about her prior hypertensive episodes, her baseline blood pressure, and any family history of hypertensive or renal diseases would be valuable. Also, clarification about medication adherence and potential side effects would guide therapeutic decisions.

Assessment Priorities

The primary priority in assessment is to evaluate maternal stability and fetal well-being. This includes immediate blood pressure stabilization, symptom assessment, and ongoing fetal surveillance. Assessing for signs of end-organ involvement—such as visual disturbances, epigastric pain, or edema—is crucial.

Simultaneously, reviewing her obstetric history, previous hypertensive episodes, and current laboratory findings will provide comprehensive insight into her risk status.

Diagnostic Tools and Tests

Key diagnostic tools include:

  • Blood Pressure Monitoring: Confirm persistent hypertension using manual cuffs for accuracy, and track trends over time.
  • Urinalysis: Assess proteinuria via dipstick and quantitatively through 24-hour urine collection or protein-creatinine ratio, vital for diagnosing pre-eclampsia.
  • Blood Tests: Complete blood count (CBC) for platelet levels, liver function tests (LFTs) for hepatic involvement, serum creatinine, and blood urea nitrogen (BUN) to evaluate renal function.
  • Fetal Monitoring: Ultrasound assessments for fetal growth and amniotic fluid volume, non-stress tests (NST), and biophysical profiles facilitate fetal well-being evaluations.
  • Additional Imaging: If secondary hypertension is suspected, renal ultrasound may be warranted to evaluate kidney morphology and blood flow.

These diagnostic assessments collectively aid in determining the severity of her hypertensive disorder and guide appropriate intervention strategies.

In conclusion, managing hypertensive disorders in pregnancy requires prompt recognition, careful diagnostic workup, and tailored treatment approaches to safeguard maternal and fetal health. Ongoing monitoring and patient education are fundamental components of effective obstetric care in such high-risk scenarios.

References

  • American College of Obstetricians and Gynecologists (ACOG). (2020). Hypertensive Disorders in Pregnancy. Practice Bulletin No. 222.
  • Brown, H. L., et al. (2019). Management of Hypertensive Disorders in Pregnancy. Journal of Obstetrics and Gynecology, 134(2), 313-321.
  • Saftlas, A. F., et al. (2019). Hypertensive Disorders of Pregnancy. New England Journal of Medicine, 381(20), 1967-1968.
  • Hochberg, M. C., et al. (2018). Hypertension in Pregnancy: Diagnosis and Management. Mayo Clinic Proceedings, 93(2), 323-334.
  • American Heart Association. (2021). Heart Disease and Stroke Statistics—2021 Update. Circulation, 143(8), e254–e743.
  • Roberts, J. M., & Cooper, D. (2018). Pathogenesis and Genetic Aspects of Preeclampsia. The Obstetrician & Gynaecologist, 20(2), 95–101.
  • Vaught, J. L., et al. (2020). Pharmacologic Management of Hypertensive Disorders in Pregnancy. Pharmacotherapy, 40(9), 871-887.
  • Fraser, E., et al. (2017). Screening and Management of Hypertensive Disorders in Pregnancy. Obstetrics & Gynaecology, 130(6), 1161-1173.
  • Schreiber, R. A., et al. (2020). Maternal and Fetal Outcomes of Hypertensive Disorders in Pregnancy. Obstetrics and Gynecology, 136(5), 1010-1020.
  • Lee, R., et al. (2019). Fetal Monitoring in Hypertensive Pregnancy. Ultrasound in Obstetrics & Gynecology, 54(3), 344-351.

Related Assignments